Phase 2 CENTAUR clinical trial for AMX0035 shows promising results

September 2, 2020 – A study published today in the New England Journal of Medicine shows that AMX0035, an experimental therapy, has promise for slowing the progression of ALS.

AMX0035 is an oral drug that contains two small molecules, which when combined, aim to preserve motor neuron health in people living with ALS, thereby delaying the progression of symptoms. Results from the Phase 2 CENTAUR clinical trial, sponsored by the pharmaceutical company Amylyx, showed that AMX0035 was safe and slowed the rate of decline in people living with ALS on the therapy compared to those on placebo. All clinical trial participants were measured and assessed over 24 weeks primarily based on the ALS Functional Rating Scale-Revised (ALSFRS-R). The preliminary data also showed potential benefits in areas including measures of muscle strength, breathing and hospitalization frequency. In addition, many participants in the trial were also already taking riluzole and Radicava (edaravone), meaning the effects observed were on top of that for the current standard of care.

ALS Canada has been in contact with Amylyx for many years and has continually advocated to have the company include Canada in their immediate future plans. We remain committed to bringing forward the needs of people living with ALS and to engage in meaningful dialogue that demonstrates the urgent need for access within the ALS community. The positive results from this study represent another step forward in developing new therapies that will one day transform the reality of living with ALS.

You can read more about the results here.